[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634096":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":30,"studyPopulation":33,"armGroups":34,"interventions":30,"overallOfficials":30,"centralContacts":36,"locations":30,"responsibleParty":42,"collaborators":30,"id":45,"slug":30,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":30,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":30,"studyType":57,"phases":30,"briefSummary":58,"conditions":59,"keywords":30,"overallStatus":61,"whyStopped":30,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":30},{"fullName":5,"class":6},"Ondokuz Mayıs University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":30,"otherOutcomes":30},[9,13,16,19,22,25,28],{"measure":10,"description":11,"timeFrame":12},"Expanded Disability Status Scale (EDSS)","The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.","Baseline",{"measure":14,"description":15,"timeFrame":12},"Standardized Mini-Mental Test","The Standardized Mini-Mental Test (MMT\u002FMMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.",{"measure":17,"description":18,"timeFrame":12},"Symbol Digit Modalities Test","The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination.\n\nScore range: Typically 0 to \\~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function",{"measure":20,"description":21,"timeFrame":12},"Multiple Sclerosis Impact Scale (MSIS-29)","Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)",{"measure":23,"description":24,"timeFrame":12},"Glial Fibrillary Acidic Protein (GFAP)","This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)",{"measure":26,"description":27,"timeFrame":12},"Neurofilament Light Chain (NfL)","This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).",{"measure":29,"description":27,"timeFrame":12},"Vascular Endothelial Growth Factor (VEGF)",null,{"allocation":30,"interventionModel":30,"interventionModelDescription":30,"primaryPurpose":30,"observationalModel":6,"timePerspective":32,"maskingInfo":30},"CROSS_SECTIONAL","Progressive Multiple Sclerosis",[35],{"label":33,"type":30,"description":30,"interventionNames":30},[37],{"name":38,"role":39,"phone":40,"phoneExt":30,"email":41},"Seda Nur Kemer","CONTACT","+903623121919","sedakemer@gmail.com",{"type":43,"investigatorFullName":38,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Lecturer, Department of Physiotherapy and Rehabilitation","100634096",false,"NCT07535242","Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS","Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis","Inclusion Criteria:\n\n* Confirmed diagnosis of MS\n* Progressive type MS\n* Voluntary participation\n* Age between 18-60 years\n* Cooperative\n* EDSS score ≥ 5.5\n\nExclusion Criteria:\n\n* Presence of another neurological disorder\n* Change in medication within the last 3 months\n* Relapse within the last 3 months","ALL","18 Years","60 Years",{"count":55,"type":56},22,"ESTIMATED","OBSERVATIONAL","This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.",[60],"Multiple Sclerosis","NOT_YET_RECRUITING","2026-04-14",{"date":64,"type":65},"2026-04-17","ACTUAL",{"date":67,"type":56},"2026-04-21",{"date":69,"type":56},"2026-05-05",{"name":5,"class":6}]